Our Take
The proposal responds to completed deals, not prevented ones—a reactive legislative posture that may tighten future screening but does not address what already happened.
Why it matters
Biotech has escaped the scrutiny applied to semiconductors and AI; adding it to COINS Act oversight signals Congress now sees drug development as strategically sensitive. For companies with China exposure, this reshapes deal review timelines.
Do this week
Corporate development and government affairs: audit existing China biotech partnerships and flag those in clinical or manufacturing stages to legal and compliance before formal bill language circulates.
Congress targets China biotech deals
A bipartisan House proposal would add biotechnology to the Committee on Foreign Investment in the United States (CFIUS) review process and expand the COINS Act, which currently covers commerce in semiconductors and related hardware. The move follows two significant transactions: Pfizer's deal involving collaboration with a China-based partner and Bristol Myers' biotech arrangement, both of which proceeded without blocking.
Rep. John Moolenaar and Rep. Debbie Dingell are driving the effort. The timing reflects U.S. intelligence assessments that China's pharmaceutical development capacity poses a competitive and national security threat, particularly in advanced therapeutics and critical drug manufacturing.
BioPharma Dive reported the proposal as part of a broader tightening of tech and life-sciences export controls.
Biotech was not on the list
Unlike semiconductors, AI models, and certain defense-grade chemicals, biotechnology has operated in a regulatory gray zone. CFIUS reviews foreign investment, but biotech companies and partnerships have not faced the same level of pre-deal scrutiny as chip or defense-adjacent sectors.
Adding biotech to formal controls shifts the burden. Companies will now need to anticipate longer review cycles, potential deal restructuring, and possible rejection. The Pfizer and Bristol Myers deals likely proceeded under older assumptions about what counted as "sensitive."
This is not a tariff or subsidy play. It is control-list expansion, which affects deal timing and structure more directly than pricing.
What to do now
If your organization has biotech operations, manufacturing relationships, or licensing deals touching China, review the current terms and flag any that involve clinical data, manufacturing IP, or foundational research. CFIUS review can take 30 to 90 days; planned transactions should budget for that.
Watch the bill's language when it drops. The definition of "biotechnology" matters. Does it cover contract manufacturing only, or does it capture equity stakes in early-stage firms? Does it apply retroactively to signed agreements? These details will determine exposure.
Regulatory affairs should brief the board on deal approval processes now, before the rule hardens. Delays in China deals are coming; planning for them is cheaper than surprise rejection.